Global 10 Valent Pneumococcal Polysaccharide Vaccine Market Size By Type (Single Dose Vial, Pre-filled Syringe), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global 10 Valent Pneumococcal Polysaccharide Vaccine Market was valued at USD 2.1 billion in 2023 and is expected to surpass USD 4.3 billion by 2031, growing at a CAGR of 9.2% during the forecast period of 2023 to 2031. The market is driven by the increasing prevalence of pneumococcal infections, rising immunization coverage in children and adults, and supportive government initiatives promoting universal vaccination programs. The 10-valent pneumococcal conjugate vaccine, covering 10 serotypes of Streptococcus pneumoniae, is gaining traction due to its safety, efficacy, and broad protective capabilities, especially in emerging economies.

Drivers:

1. Rising Incidence of Pneumococcal Diseases:

Pneumonia, meningitis, and sepsis caused by Streptococcus pneumoniae continue to pose serious health threats, particularly to children under five and older adults. The demand for effective preventive vaccines, including the 10-valent polysaccharide variant, is surging globally.

2. Government Immunization Programs:

Global health organizations and governments are aggressively promoting pneumococcal vaccination through national immunization schedules and Gavi-supported campaigns. These initiatives are driving large-scale vaccine procurement and distribution.

3. Cost-Effective Alternative to Higher Valent Vaccines:

The 10-valent vaccine serves as a cost-efficient option for middle- and low-income countries when compared to the 13-valent or newer higher-valent alternatives, making it a favorable choice for mass immunization.

Restraints:

1. Limited Serotype Coverage Compared to Advanced Vaccines:

The availability of vaccines with broader serotype coverage (e.g., 13-valent, 15-valent) can limit the uptake of the 10-valent vaccine, especially in high-income regions where disease strain variation is more complex.

2. Regulatory Delays in Emerging Markets:

Delayed approvals and inconsistent regulatory pathways in several developing countries hinder the timely adoption of the 10-valent pneumococcal vaccine.

Opportunity:

1. Market Expansion in Sub-Saharan Africa and Southeast Asia:

These regions bear a significant burden of pneumococcal diseases and are now scaling up their healthcare infrastructures and vaccination outreach programs, presenting a lucrative growth opportunity.

2. Integration into Adult Vaccination Schedules:

As aging populations become more vulnerable to pneumococcal infections, expanding the use of the 10-valent vaccine into adult immunization programs could significantly boost market demand.

Market by System Type Insights:

Based on formulation type, lyophilized (freeze-dried) vaccines held the dominant market share in 2023 due to their longer shelf life and ease of storage and transport, especially in regions with limited cold chain capabilities. However, the liquid formulation segment is gaining traction, particularly in urban healthcare settings, owing to its ease of administration and reduced preparation time.

Market by End-use Insights:

The pediatric segment represented the largest market share in 2023, as infants are the primary target population for pneumococcal immunization. The increasing integration of this vaccine into newborn immunization schedules has driven its dominance. The adult segment is projected to witness the highest growth rate, supported by rising awareness and governmental policy shifts toward adult vaccination.

Market by Regional Insights:

Latin America and Africa emerged as the largest regional markets in 2023, driven by strong public health campaigns and bulk procurement under international vaccine alliance programs. Asia-Pacific is forecasted to grow at the fastest rate during the forecast period, owing to large birth cohorts, improving healthcare access, and increasing support from global vaccine funding initiatives.

Competitive Scenario:

Key players in the Global 10 Valent Pneumococcal Polysaccharide Vaccine Market include:

Serum Institute of India Pvt. Ltd.

GlaxoSmithKline plc

Panacea Biotec

Biological E. Limited

MSD (Merck & Co., Inc.)

Bharat Biotech

Pfizer Inc.

These companies focus on increasing production capacity, securing WHO prequalification, and expanding market presence in developing countries. For instance:

In 2023, Serum Institute of India expanded its supply agreement with Gavi to deliver 10-valent pneumococcal vaccines to low-income countries.

In 2024, GSK launched an enhanced distribution strategy in Southeast Asia, improving last-mile vaccine delivery logistics.

In 2025, Panacea Biotec announced regulatory approval of its 10-valent vaccine in Latin America, marking its entry into the regional market.

Scope of Work – Global 10 Valent Pneumococcal Polysaccharide Vaccine Market

Key Market Developments:

2023: Serum Institute of India began large-scale distribution of its WHO-prequalified 10-valent vaccine across Africa.

2024: GSK’s 10-valent pneumococcal vaccine received marketing approval in multiple Southeast Asian countries.

2025: Panacea Biotec secured strategic procurement deals with government agencies in Latin America.

FAQs:

1) What is the current market size of the Global 10 Valent Pneumococcal Polysaccharide Vaccine Market?

The market was valued at USD 2.1 billion in 2023.

2) What is the major growth driver of the Global 10 Valent Pneumococcal Polysaccharide Vaccine Market?

The primary growth driver is the rising incidence of pneumococcal diseases and increasing global immunization efforts.

3) Which is the largest region during the forecast period in the Global 10 Valent Pneumococcal Polysaccharide Vaccine Market?

Latin America and Africa collectively hold the largest market share due to bulk immunization campaigns.

4) Which segment accounted for the largest market share in the Global 10 Valent Pneumococcal Polysaccharide Vaccine Market?

The pediatric segment dominated the market in 2023.

5) Who are the key market players in the Global 10 Valent Pneumococcal Polysaccharide Vaccine Market?

Key players include Serum Institute of India, GSK, Panacea Biotec, Biological E., MSD, Bharat Biotech, and Pfizer.

Let me know if you’d like the same structure for other vaccine types or related therapeutic segments.